(Q35122766)

6 August 2017

1 reference

title

Severe community-acquired pneumonia: what's in a name? (English)

1 reference

6 August 2017

Severe community-acquired pneumonia: whatʼs in a name? (English)

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

31 December 2023

1 reference

severity of illness index

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12734448

31 December 2023

2

Marc J. M. Bonten

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12734448

31 December 2023

author name string

Jan Jelrik Oosterheert

1

1 reference

6 August 2017

Eelko Hak

3

1 reference

6 August 2017

Margriet M. E. Schneider

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12734448

31 December 2023

Andy I. M. Hoepelman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12734448

31 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12734448

31 December 2023

publication date

1 April 2003

1 reference

full work available at URL

6 August 2017

https://journals.lww.com/00001432-200304000-00012

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Current Opinion in Infectious Diseases

31 December 2023

published in

1 reference

6 August 2017

volume

16

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

153-159

1 reference

Community-acquired pneumonia: the annual cost to the National Health Service in the UK.

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis

31 December 2023

2

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe Community-Acquired Pneumonia

31 December 2023

3

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors

31 December 2023

4

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

The pulmonary physician in critical care . 3: critical care management of community acquired pneumonia

31 December 2023

5

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

31 December 2023

6

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Defining severe community-acquired pneumonia

31 December 2023

8

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

A prediction rule to identify low-risk patients with community-acquired pneumonia

31 December 2023

9

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe community-acquired pneumonia. Assessment of severity criteria

31 December 2023

10

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria

31 December 2023

11

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Etiology of severe pneumonia in the very elderly

31 December 2023

12

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia

31 December 2023

13

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions.

31 December 2023

14

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands

31 December 2023

15

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe community-acquired pneumonia. Risk factors and follow-up epidemiology.

31 December 2023

16

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Guidelines for severe community-acquired pneumonia in the western world

31 December 2023

17

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity

31 December 2023

18

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia

31 December 2023

19

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe community-acquired pneumonia due to Acinetobacter baumannii.

31 December 2023

20

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

31 December 2023

21

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness

31 December 2023

22

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients

31 December 2023

23

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina

31 December 2023

24

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy

31 December 2023

25

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

31 December 2023

26

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Simplified Prediction Rule for Prognosis of Patients With Severe Community-Acquired Pneumonia in ICUs

31 December 2023

27

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors

31 December 2023

28

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

MBL genotype and risk of invasive pneumococcal disease: a case-control study

31 December 2023

29

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations

31 December 2023

30

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias

31 December 2023

31

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee

31 December 2023

32

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis

31 December 2023

33

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization

31 December 2023

34

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy

31 December 2023

36

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Nederlands Tijdschrift voor Geneeskunde

31 December 2023

37

142

952

Kasteren MEE van, W Wijnands

publication date

1998

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

31 December 2023

38

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia

31 December 2023

39

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states : 1993, 1995, and 1997.

31 December 2023

41

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

31 December 2023

42

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals

31 December 2023

43

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Severe pneumonia and a second antibiotic.

31 December 2023

44

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

The best treatment for pneumonia: new clues, but no definitive answers

31 December 2023

45

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Community-acquired lower respiratory tract infections: etiology and treatment

31 December 2023

46

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

31 December 2023

47

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

31 December 2023

48

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Treatment of drug-resistant pneumococcal pneumonia

31 December 2023

49

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

31 December 2023

51

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Influenza vaccinations: who needs them and when?

31 December 2023

52

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Resistance among Streptococcus pneumoniae: Implications for drug selection

31 December 2023

53

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Vaccines for pneumonia and new antiviral therapies

31 December 2023

54

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Pneumococcal vaccination of the elderly: do we need another trial?

31 December 2023

55

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

31 December 2023

56

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study

31 December 2023

57

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Clinical practice. Influenza vaccination for healthy young adults

31 December 2023

58

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective

31 December 2023

59

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries

31 December 2023

60

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

31 December 2023

61

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

Prevention and early treatment of influenza in healthy adults

31 December 2023

62

1 reference

https://api.crossref.org/works/10.1097/00001432-200304000-00012

31 December 2023

Identifiers

1 reference

6 August 2017

1 reference